Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that ...

NYSE:BDX) BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...

Becton Dickinson and Co (BDX) stock saw a decline, ending the day at $232.59 which represents a decrease of $-3.21 or -1.36% from the prior close of $235.8. The stock opened at $237 and touched a low ...